NEW YORK, March 5, 2014 /PRNewswire/ --
Editor Note: For more information about this release, please
scroll to bottom.
Today, Analysts Review released its analysts' notes regarding
Community Health Systems, Inc. (NYSE: CYH), United Therapeutics
Corporation (NASDAQ: UTHR), Thoratec Corp. (NASDAQ: THOR), Albany
Molecular Research Inc. (NASDAQ: AMRI), and Cytokinetics, Inc.
(NASDAQ: CYTK). Private wealth members receive these notes ahead of
publication. To reserve complementary membership, limited openings
are available at:
http://www.AnalystsReview.com/register
Community Health Systems, Inc. Analyst
Notes
On February 27, 2014, Community
Health Systems, Inc.'s (Community Health Systems) stock rose 2.57%
to end the day at $42.25 compared to
the previous day's closing price of $41.19. The Company's stock went down 1.42% over
the past three trading days, compared to the Dow Jones Industrial
Average which rose 0.40% during the same trading period. The full
analyst notes on Community Health Systems, Inc. are available to
download free of charge at:
http://www.AnalystsReview.com/03052014/CYH/report.pdf
United Therapeutics Corporation
Analyst Notes
On February 25, 2014, United
Therapeutics Corp. (United Therapeutics) reported its Q4 2013 and
full-year 2013 financial results. For the quarter, the Company
reported total revenues of $289.0
million compared to $243.8
million in Q4 2012, while annual revenues came in at
$1.1 billion compared to $916.1 million for full year 2012. Net loss
totaled $30.3 million or $0.60 per diluted share for Q4 2013 compared to
net income of $83.3 million or
$1.60 per diluted share in Q4 2012.
For its full-year 2013, net income totaled $174.6 million or $3.28 per diluted share, compared to $305.4 million, or $5.71 per diluted share in full year 2012.
Commenting on the results, Martine
Rothblatt, Ph.D., United Therapeutics' Chairman and CEO,
stated, "United Therapeutics continued to deliver strong results in
2013, reflecting growing demand for our Remodulin®, Tyvaso® and
Adcirca® products. In addition we successfully brought a fourth
product, Orenitram™, to FDA approval and continued enrolling
patients in two pivotal trials with the goal of demonstrating that
our oral prostacyclin analogues reduce morbidity and mortality in
patients with pulmonary arterial hypertension." The full analyst
notes on United Therapeutics Corporation are available to download
free of charge at:
http://www.AnalystsReview.com/03052014/UTHR/report.pdf
Thoratec Corp. Analyst Notes
On February 26, 2014, Thoratec
Corp. (Thoratec) announced that the Company will be participating
in the Barclays Global Healthcare Conference, which is scheduled on
March 11, 2014, Tuesday. The Company
stated that the presentation will be led by Taylor C. Harris, Vice President and CFO, and
will begin at 9:00 a.m. EDT or
6:00 a.m. PDT. Thoratec added that a
webcast of the presentation will be available at the Company's
website. The full analyst notes on Thoratec Corp. are available to
download free of charge at:
http://www.AnalystsReview.com/03052014/THOR/report.pdf
Albany Molecular Research Inc. Analyst
Notes
On February 27, 2014, Albany
Molecular Research Inc. (AMRI) announced that it will be presenting
at the Barclays Global Healthcare Conference on March 12, 2014, Wednesday at 2:00 p.m. ET. According to the Company,
William S. Marth, President and CEO
of AMRI, will represent the Company at the conference. AMRI stated
that a webcast of the presentation can be accessed at the Investor
Relations' section of the Company's website, where it will be
archived for 90 days after the presentation. The full analyst notes
on Albany Molecular Research Inc. are available to download free of
charge at:
http://www.AnalystsReview.com/03052014/AMRI/report.pdf
Cytokinetics, Inc. Analyst Notes
On February 25, 2014,
Cytokinetics, Inc. (Cytokinetics) announced the closing of an
underwritten public offering of 4,375,000 shares of its common
stock, along with 656,250 additional shares of its common stock in
accordance with the full exercise of the underwriters' option to
purchase additional shares. The Company stated that the public
offering price was $8.00 per share
and total net proceeds to Cytokinetics from the public offering are
expected to be c.$37.4 million, after
deducting the underwriting discount and estimated offering expenses
payable by Cytokinetics. Cytokinetics added that it plans to use
these net proceeds for research and development and other general
corporate purposes, including working capital. The full analyst
notes on Cytokinetics, Inc. are available to download free of
charge at:
http://www.AnalystsReview.com/03052014/CYTK/report.pdf
About Analysts Review
We provide our members with a simple and reliable way to leverage
our economy of scale. Most investors do not have time to track all
publicly traded companies, much less perform an in-depth review and
analysis of the complexities contained in each situation. That's
where Analysts Review comes in. We provide a single unified
platform for investors' to hear about what matters. Situation
alerts, moving events, and upcoming opportunities.
EDITOR NOTES:
- This is not company news. We are an independent source and our
views do not reflect the companies mentioned.
- Information in this release is fact checked and produced on a
best efforts basis and reviewed by Nidhi Vatsal, a CFA
charterholder. However, we are only human and are prone to making
mistakes. If you notice any errors or omissions, please notify us
below.
- This information is submitted as a net-positive to companies
mentioned, to increase awareness for mentioned companies to our
subscriber base and the investing public.
- If you wish to have your company covered in more detail by our
team, or wish to learn more about our services, please contact us
at pubco [at] AnalystsReview.com.
- For any urgent concerns or inquiries, please contact us
at compliance [at] AnalystsReview.com.
- Are you a public company? Would you like to see similar
coverage on your company? Send us a full investors' package to
research [at] AnalystsReview.com for consideration.
COMPLIANCE PROCEDURE
Content is researched, written and reviewed on a best-effort
basis. This document, article or report is prepared and authored by
Analysts Review. An outsourced research services provider
represented by Nidhi Vatsal, CFA, has only reviewed the information
provided by Analysts Review in this article or report according to
the Procedures outlined by Analysts Review. Analysts Review is not
entitled to veto or interfere in the application of such procedures
by the outsourced provider to the articles, documents or reports,
as the case may be.
NOT FINANCIAL ADVICE
Analysts Review makes no warranty, expressed or implied, as to
the accuracy or completeness or fitness for a purpose (investment
or otherwise), of the information provided in this document. This
information is not to be construed as personal financial advice.
Readers are encouraged to consult their personal financial advisor
before making any decisions to buy, sell or hold any securities
mentioned herein.
NO WARRANTY OR LIABILITY ASSUMED
Analysts Review is not responsible for any error which may be
occasioned at the time of printing of this document or any error,
mistake or shortcoming. No liability is accepted by Analysts Review
whatsoever for any direct, indirect or consequential loss arising
from the use of this document. Analysts Review expressly disclaims
any fiduciary responsibility or liability for any consequences,
financial or otherwise arising from any reliance placed on the
information in this document. Analysts Review does not (1)
guarantee the accuracy, timeliness, completeness or correct
sequencing of the information, or (2) warrant any results from use
of the information. The included information is subject to change
without notice.
CFA® and Chartered Financial Analyst® are registered trademarks
owned by CFA Institute.
http://www.AnalystsReview.com/
SOURCE Analysts Review